-
Biomea Fusion NASDAQ:BMEA Biomea Fusion, Inc. operates as a biopharmaceutical company. The Company focuseS on the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Biomea Fusion serves customers in the United States.
Location: | Website: www.biomeafusion.com | Industry: Research and Development in Biotechnology | Sector: Professional, Scientific, and Technical Services
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
72.01M
Cash
87.95M
Avg Qtr Burn
-28.18M
Short % of Float
51.41%
Insider Ownership
25.02%
Institutional Own.
64.49%
Qtr Updated
09/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
BMF-219 (icovamenib) Details Type 2 diabetes | Phase 2b Data readout | |
Phase 2 Data readout | ||
Phase 2 Initiation | ||
BMF-219 (icovamenib) Details Solid tumor/s, Colorectal cancer , Pancreatic cancer, Non-small cell lung carcinoma | Phase 1/2 Data readout | |
BMF-219 (icovamenib) Details Acute myeloid leukemia, Acute lymphoblastic leukemia | Phase 1 Data readout | |
BMF-500 Details Leukemia | Phase 1 Update |